ES3018557T3 - Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona - Google Patents
Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona Download PDFInfo
- Publication number
- ES3018557T3 ES3018557T3 ES16704896T ES16704896T ES3018557T3 ES 3018557 T3 ES3018557 T3 ES 3018557T3 ES 16704896 T ES16704896 T ES 16704896T ES 16704896 T ES16704896 T ES 16704896T ES 3018557 T3 ES3018557 T3 ES 3018557T3
- Authority
- ES
- Spain
- Prior art keywords
- rpl554
- salt
- salts
- acid
- ethane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502260A GB201502260D0 (en) | 2015-02-11 | 2015-02-11 | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| PCT/GB2016/050313 WO2016128742A1 (en) | 2015-02-11 | 2016-02-10 | Salt of a pyrimido[6,1-a]isoquinolin-4-one compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3018557T3 true ES3018557T3 (es) | 2025-05-16 |
Family
ID=52781414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16704896T Active ES3018557T3 (es) | 2015-02-11 | 2016-02-10 | Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona |
Country Status (13)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015261239B2 (en) | 2014-05-12 | 2020-02-27 | Verona Pharma Plc | New treatment |
| RS62252B1 (sr) * | 2014-09-15 | 2021-09-30 | Verona Pharma Plc | Tečna inhalaciona formulacija koja sadrži rpl554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| GB201911517D0 (en) * | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| JP7712276B2 (ja) * | 2020-01-15 | 2025-07-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 三環式ｐｄｅ３／ｐｄｅ４二重阻害剤化合物の医薬組成物 |
| CA3176481A1 (en) * | 2020-04-22 | 2021-10-28 | Marjoh NAUTA | Coronavirus vaccine |
| EP4423085A1 (en) | 2021-10-29 | 2024-09-04 | Teva Pharmaceuticals International GmbH | Solid state forms of ensifentrine and process for preparation thereof |
| CN118660887A (zh) * | 2021-12-14 | 2024-09-17 | 西藏海思科制药有限公司 | 三环稠杂环类pde3/4双重抑制及其用途 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| KR20250048093A (ko) * | 2022-08-08 | 2025-04-07 | 베로나 파마 피엘씨 | 최저 폐 기능 향상을 위한 엔시펜트린(rpl-554) |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
| WO2025176871A1 (en) | 2024-02-23 | 2025-08-28 | Inke, S.A. | Process for preparing pyrimido[6,1-a]isoquinoline-4-ones |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW6284A1 (en) | 1983-05-05 | 1985-10-30 | Hoffmann La Roche | Novel pyrimidone derivatives |
| DE3816995A1 (de) | 1988-05-19 | 1989-11-23 | Hoechst Ag | Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen |
| DK1165558T3 (da) * | 1999-03-31 | 2004-02-09 | Vernalis Ltd | Pyrimido[6,1-a]isoquinolin-4-on-derivater |
| US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US7838521B2 (en) * | 2004-09-08 | 2010-11-23 | Nycomed Gmbh | 3-oxa-10-aza-phenanthrenes |
| EP2558101A4 (en) | 2010-04-15 | 2013-09-18 | Univ Mcgill | TOPICAL TREATMENTS OF PAIN |
| MX345802B (es) | 2010-08-09 | 2017-02-16 | Verona Pharma Plc * | Forma cristalina de compuesto pirimido [6, 1-a] isoquinolin-4-ona. |
| EP2647627A1 (en) * | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
| EP2968312B1 (en) | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| AU2015261239B2 (en) | 2014-05-12 | 2020-02-27 | Verona Pharma Plc | New treatment |
| RS62252B1 (sr) | 2014-09-15 | 2021-09-30 | Verona Pharma Plc | Tečna inhalaciona formulacija koja sadrži rpl554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
-
2015
- 2015-02-11 GB GB201502260A patent/GB201502260D0/en not_active Ceased
-
2016
- 2016-02-10 EP EP16704896.6A patent/EP3256472B1/en active Active
- 2016-02-10 EP EP24189714.9A patent/EP4461358A3/en active Pending
- 2016-02-10 JP JP2017541901A patent/JP7089366B2/ja active Active
- 2016-02-10 CN CN201680009645.9A patent/CN107406446B/zh active Active
- 2016-02-10 PT PT167048966T patent/PT3256472T/pt unknown
- 2016-02-10 CA CA2974605A patent/CA2974605C/en active Active
- 2016-02-10 AU AU2016217674A patent/AU2016217674B2/en active Active
- 2016-02-10 US US15/549,500 patent/US10463665B2/en active Active
- 2016-02-10 CN CN202110415666.3A patent/CN113105453A/zh active Pending
- 2016-02-10 WO PCT/GB2016/050313 patent/WO2016128742A1/en active Application Filing
- 2016-02-10 ES ES16704896T patent/ES3018557T3/es active Active
- 2016-02-10 MX MX2017010195A patent/MX382019B/es unknown
-
2017
- 2017-07-20 IL IL253595A patent/IL253595B/en active IP Right Grant
- 2017-07-27 ZA ZA2017/05112A patent/ZA201705112B/en unknown
-
2019
- 2019-09-24 US US16/580,515 patent/US11491155B2/en active Active
-
2020
- 2020-07-15 AU AU2020205281A patent/AU2020205281B2/en active Active
- 2020-11-09 JP JP2020186284A patent/JP7110303B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016217674A1 (en) | 2017-08-10 |
| JP2021046405A (ja) | 2021-03-25 |
| US11491155B2 (en) | 2022-11-08 |
| IL253595A0 (en) | 2017-09-28 |
| CN107406446A (zh) | 2017-11-28 |
| CA2974605C (en) | 2024-02-13 |
| MX2017010195A (es) | 2017-11-17 |
| CN113105453A (zh) | 2021-07-13 |
| EP4461358A2 (en) | 2024-11-13 |
| NZ733926A (en) | 2023-10-27 |
| JP7110303B2 (ja) | 2022-08-01 |
| JP7089366B2 (ja) | 2022-06-22 |
| ZA201705112B (en) | 2022-05-25 |
| US10463665B2 (en) | 2019-11-05 |
| US20180021337A1 (en) | 2018-01-25 |
| PT3256472T (pt) | 2025-04-11 |
| AU2020205281A1 (en) | 2020-08-06 |
| WO2016128742A1 (en) | 2016-08-18 |
| EP3256472A1 (en) | 2017-12-20 |
| AU2020205281B2 (en) | 2021-07-15 |
| CN107406446B (zh) | 2021-12-28 |
| IL253595B (en) | 2021-04-29 |
| EP4461358A3 (en) | 2025-01-15 |
| CA2974605A1 (en) | 2016-08-18 |
| GB201502260D0 (en) | 2015-04-01 |
| MX382019B (es) | 2025-03-13 |
| AU2016217674B2 (en) | 2020-04-30 |
| JP2018505192A (ja) | 2018-02-22 |
| EP3256472B1 (en) | 2025-03-19 |
| US20200016158A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3018557T3 (es) | Sal de un compuesto de pirimido[6,1-a]isoquinolin-4-ona | |
| ES3033142T3 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| ES2943109T3 (es) | Reducción del tamaño de las partículas de un compuesto antimuscarínico | |
| ES2814336T3 (es) | Partículas de agregado | |
| ES2970571T3 (es) | Composición farmacéutica líquida que comprende ensifentrina y glicopirrolato | |
| ES2396471T3 (es) | Procedimiento para reducir la tendencia de una sal de glicopirronio a agregarse durante el almacenamiento | |
| ES2797073T3 (es) | Partículas de inhalación que comprenden una combinación de un anticolinérgico, un corticoesteroide y un beta-adrenérgico | |
| Ali et al. | Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote | |
| ES2793905T3 (es) | Formulación que comprende glicopirrolato, método y aparato | |
| ES2726831T3 (es) | Partículas inhalables que comprenden tiotropio e indacaterol | |
| US20100210611A1 (en) | Combination therapy | |
| WO2006076222A2 (en) | Pharmaceutical formulations | |
| Akdag et al. | Formulation and characterization of mometasone furoate and formoterol fumarate containing dry powder inhaler by spray drying and homogenization methods | |
| NZ733926B2 (en) | Salt of a pyrimido[6,1-a]isoquinolin-4-one compound | |
| US20240033218A1 (en) | Dihydroergotamine dry powder formulations and methods of use | |
| ES2805434T3 (es) | Procedimiento de estabilización de tamaño de partícula | |
| ES2935112T3 (es) | Preparación de partículas micronizadas de un compuesto antimuscarínico mediante cavitación hidrodinámica | |
| Carvalho | Improved inhalation therapies of brittle powders | |
| ES2971768T3 (es) | Composición farmacéutica que contiene budesonida y formoterol |